Studies in r/r PTCL patients of second or later line treatment had a response rate ranging from 23 to 29% except brentuximab vedotin with a higher rate in CD30-positive PTCLs. Here, TNFRSF8 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.